HRP20200744T1 - Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida - Google Patents

Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida Download PDF

Info

Publication number
HRP20200744T1
HRP20200744T1 HRP20200744TT HRP20200744T HRP20200744T1 HR P20200744 T1 HRP20200744 T1 HR P20200744T1 HR P20200744T T HRP20200744T T HR P20200744TT HR P20200744 T HRP20200744 T HR P20200744T HR P20200744 T1 HRP20200744 T1 HR P20200744T1
Authority
HR
Croatia
Prior art keywords
expression
cassette
antibody
light chain
heavy chain
Prior art date
Application number
HRP20200744TT
Other languages
English (en)
Inventor
Peter Michael HUELSMANN
Hendrik Knoetgen
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20200744T1 publication Critical patent/HRP20200744T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (11)

1. Ekspresijski vektor, naznačen time, da sadrži: - kazetu za ekspresiju lakog lanca protutijela, - kazetu za ekspresiju teškog lanca protutijela i - kazetu za ekspresiju selekcijskog markera, pri čemu su kazete za ekspresiju raspoređene jednosmjerno, i pri čemu su kazete za ekspresiju raspoređene u 5' do 3' sekvence kazete za ekspresiju teškog lanca protutijela, kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera, pri čemu sve tri kazete za ekspresiju sadrže promotor humanog elongacijskog faktora 1 alfa identifikacijskog broja sekvence: 05, pri čemu kazeta za ekspresiju lakog lanca i kazeta za ekspresiju teškog lanca protutijela, sadrže signalnu sekvencu polyA goveđeg hormona rasta.
2. Ekspresijski vektor u skladu s patentnim zahtjevom 1, naznačen time, da kazete za ekspresiju ne sadrže terminacijsku sekvencu.
3. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela, sadrži barem jedan intron.
4. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela je cDNA.
5. Uporaba ekspresijskog vektora prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da je za rekombinantnu proizvodnju protutijela.
6. Uporaba ekspresijskog vektora prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da je za dobivanje stabilne stanične linije.
7. Uporaba ekspresijskog vektora prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da je za dobivanje proizvodne stanične linije.
8. Postupak za proizvodnju protutijela, naznačen time, da obuhvaća sljedeće korake: - kultiviranje eukariotske stanice koja je transficirana ekspresijskim vektorom prema bilo kojem od patentnih zahtjeva 1 do 4, i - dobivanje protutijela iz stanice ili kultivacijskog medija.
9. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da ekspresijski vektor sadrži: - prvu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira prvi laki lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, - drugu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira drugi laki lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, - treću kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira prvi teški lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, - četvrtu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira drugi teški lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, ili - prvu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira laki lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, - drugu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira prvi teški lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, i - treću kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira drugi teški lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, pri čemu laki lanac protutijela je zajednički laki lanac za oba teška lanca protutijela.
10. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 4 i 9, naznačen time, da ekspresijski vektor sadrži: - kazetu za ekspresiju lakog lanca protutijela, - prvu kazetu za ekspresiju teškog lanca protutijela, - drugu kazetu za ekspresiju teškog lanca protutijela i - kazetu za ekspresiju selekcijskog markera, pri čemu je barem jedna od kazete za ekspresiju teškog lanca protutijela i kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera, raspoređena jednosmjerno, i pri čemu su jednosmjerne kazete za ekspresiju raspoređene u 5' do 3' sekvenci kazete za ekspresiju teškog lanca protutijela, kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera.
11. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 4 i 9 do 10, naznačen time, da ekspresijski vektor sadrži: - prvu kazetu za ekspresiju lakog lanca protutijela, - drugu kazetu za ekspresiju lakog lanca protutijela, - prvu kazetu za ekspresiju teškog lanca protutijela, - drugu kazetu za ekspresiju teškog lanca protutijela, i - kazetu za ekspresiju selekcijskog markera, pri čemu su jedna od kazeta za ekspresiju teškog lanca protutijela i jedna od kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera, raspoređene jednosmjerno, i pri čemu su jednosmjerne kazete za ekspresiju raspoređene u 5' do 3' sekvenci kazete za ekspresiju teškog lanca protutijela, kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera.
HRP20200744TT 2011-12-22 2020-05-08 Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida HRP20200744T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11195363 2011-12-22
PCT/EP2012/076167 WO2013092723A1 (en) 2011-12-22 2012-12-19 Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
EP12813822.9A EP2794878B1 (en) 2011-12-22 2012-12-19 Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides

Publications (1)

Publication Number Publication Date
HRP20200744T1 true HRP20200744T1 (hr) 2020-07-24

Family

ID=47557065

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200744TT HRP20200744T1 (hr) 2011-12-22 2020-05-08 Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida

Country Status (16)

Country Link
US (3) US9963511B2 (hr)
EP (2) EP2794878B1 (hr)
JP (4) JP2015502165A (hr)
KR (3) KR102184059B1 (hr)
CN (2) CN104114701A (hr)
BR (1) BR112014012667A2 (hr)
CA (2) CA2853955C (hr)
ES (1) ES2791758T3 (hr)
HK (2) HK1203546A1 (hr)
HR (1) HRP20200744T1 (hr)
MX (1) MX355625B (hr)
PL (1) PL2794878T3 (hr)
RU (2) RU2756106C2 (hr)
SG (3) SG11201403223PA (hr)
SI (1) SI2794878T1 (hr)
WO (1) WO2013092723A1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963511B2 (en) * 2011-12-22 2018-05-08 Hoffmann-La Roche Inc. Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
AU2015289386A1 (en) 2014-07-18 2017-03-09 Celltheon Corporation Methods and compositions for expression of polypeptides in a cell
KR102559149B1 (ko) * 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CN112626121B (zh) * 2020-12-29 2024-04-09 苏州博腾生物制药有限公司 三筛选标记的抗体表达载体以及应用
CN113512537A (zh) * 2021-08-19 2021-10-19 长春生物制品研究所有限责任公司 高表达人促卵泡激素的重组cho细胞株及其构建方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
JP2002525047A (ja) * 1998-09-16 2002-08-13 ネクシア バイオテクノロジーズ， インコーポレイテッド 尿における組換え蛋白質の産生
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CN101670105B (zh) 2000-02-24 2014-08-06 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
AU2001261628A1 (en) * 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE432343T1 (de) * 2000-11-17 2009-06-15 Kyowa Hakko Kirin Co Ltd Expression xenogener (menschlicher) immunglobuline in geklonten, transgenen rindern
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
CN1494553A (zh) 2001-01-29 2004-05-05 IDECҩ�﹫˾ 改变的抗体及其使用方法
EP1404851A4 (en) 2001-06-08 2005-05-25 Icon Genetics Inc PRODUCTION OF PLANT PROTEINS
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
WO2003029412A2 (en) * 2001-10-02 2003-04-10 Institut Clayton De La Recherche Restricted expression lentivial vectors
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EA007905B1 (ru) 2001-11-16 2007-02-27 Байоджен Айдек Инк. Полицистронная экспрессия антител
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
DE60336548D1 (de) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SI2289936T1 (sl) 2002-12-16 2017-10-30 Genentech, Inc. Imunoglobulinske variante in njihove uporabe
PT1583830E (pt) 2003-01-07 2006-11-30 Symphogen As Método para produzir proteínas policlonais recombinantes
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JP4685764B2 (ja) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
LT2380911T (lt) 2003-11-05 2018-07-10 Roche Glycart Ag Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2005089285A2 (en) 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
ES2730216T3 (es) * 2005-05-18 2019-11-08 Biofactura Inc Composiciones y métodos para selección metabólica de células transfectadas
CN101292036B (zh) 2005-10-21 2016-04-13 弗·哈夫曼-拉罗切有限公司 用于重组表达多肽的方法
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008077545A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Selection method
CN100999732A (zh) * 2006-12-30 2007-07-18 北京济普霖生物技术有限公司 一种利用动物乳腺生产抗人cd20单克隆抗体的方法
NZ580378A (en) 2007-03-30 2012-11-30 Abbott Lab Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
KR101183764B1 (ko) 2007-06-29 2012-09-17 에프. 호프만-라 로슈 아게 프로모터
TR201816045T4 (tr) 2007-10-12 2018-11-21 Hoffmann La Roche Birden fazla nükleik asitten protein ekspresyonu.
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2585502T3 (es) * 2007-12-21 2016-10-06 Novartis Ag Vector de expresión en mamíferos
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN101550425B (zh) * 2008-03-31 2011-03-30 北京大学 一种可调控的肝损伤动物模型的制作方法及其专用载体
RU2731084C2 (ru) 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
JP5788796B2 (ja) 2008-08-28 2015-10-07 ノバルティス アーゲー 終止コドンのリードスルーによるポリペプチドアイソフォームの細胞表面提示
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
EP2435473B1 (en) 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
JP4525863B1 (ja) 2009-06-05 2010-08-18 東洋紡績株式会社 高生産性細胞の樹立のための発現ベクター及び高生産性細胞
JP4547643B1 (ja) * 2009-06-05 2010-09-22 東洋紡績株式会社 クローニングに最適化された発現ベクター
CN101596316A (zh) * 2009-06-12 2009-12-09 长沙新生康源生物医药有限公司 表达FoxMlsiRNA的重组腺病毒及其在肿瘤治疗和预防中的应用
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
WO2011033375A2 (en) * 2009-09-18 2011-03-24 Selexis S.A. Products and methods for enhanced transgene expression and processing
JP5506339B2 (ja) 2009-11-19 2014-05-28 三菱重工業株式会社 方向制御装置および方向制御方法
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
RU2598255C2 (ru) * 2010-12-15 2016-09-20 Интер-Юниверсити Рисерч Инститьют Корпорейшн Рисерч Организейшн Оф Информейшн Энд Системз Способ получения белка
US9963511B2 (en) * 2011-12-22 2018-05-08 Hoffmann-La Roche Inc. Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
KR102288857B1 (ko) * 2013-12-20 2021-08-11 노파르티스 아게 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법

Also Published As

Publication number Publication date
ES2791758T3 (es) 2020-11-05
SI2794878T1 (sl) 2020-07-31
RU2628703C2 (ru) 2017-08-21
CN104114701A (zh) 2014-10-22
HK1250743A1 (zh) 2019-01-11
EP2794878B1 (en) 2020-03-18
RU2756106C2 (ru) 2021-09-28
US20140370547A1 (en) 2014-12-18
KR102080356B1 (ko) 2020-02-24
CA3125875A1 (en) 2013-06-27
JP2021072867A (ja) 2021-05-13
US10882910B2 (en) 2021-01-05
HK1203546A1 (en) 2015-10-30
EP2794878A1 (en) 2014-10-29
JP7057456B2 (ja) 2022-04-19
SG10201805622QA (en) 2018-08-30
WO2013092723A1 (en) 2013-06-27
KR20140113915A (ko) 2014-09-25
BR112014012667A8 (pt) 2017-06-20
JP2015502165A (ja) 2015-01-22
RU2017127208A3 (hr) 2021-04-02
PL2794878T3 (pl) 2020-07-27
JP2019071903A (ja) 2019-05-16
KR102184059B1 (ko) 2020-11-30
SG10201601882PA (en) 2016-04-28
SG11201403223PA (en) 2014-07-30
MX355625B (es) 2018-04-25
MX2014007360A (es) 2014-08-01
KR102280111B1 (ko) 2021-07-21
RU2017127208A (ru) 2019-02-14
EP3816284A1 (en) 2021-05-05
BR112014012667A2 (pt) 2018-10-09
RU2014129729A (ru) 2016-02-20
KR20200008017A (ko) 2020-01-22
US20180334505A1 (en) 2018-11-22
CA2853955C (en) 2021-09-28
JP2017060519A (ja) 2017-03-30
US9963511B2 (en) 2018-05-08
US20210054083A1 (en) 2021-02-25
KR20200133827A (ko) 2020-11-30
CN107881196A (zh) 2018-04-06
CA2853955A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
HRP20200744T1 (hr) Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
HRP20221383T1 (hr) Kombinacije elemenata ekspresijskog vektora, novi proizvodni postupci dobivanja stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
JP2010519251A5 (hr)
IL299249B2 (en) Genetically modified immune cells that include adapted shrna-microRNA (shrnamir)
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
MX2010003622A (es) Expresion proteinica a partir de acidos nucleicos multiples.
CL2012001258A1 (es) Un polipeptido de factor de von willebrand (fvw) aislado que comprende un dominio de union a factor viii (fviii), donde dicho polipeptido carece de algunos dominios del fvw, comprende una secuencia de aminoacidos de fc de inmunoglobulina; composicion y complejo proteico que lo comprende; celula que expresa dicho polipeptido; celula que expresa dicho complejo proteico; composición que comprende el complejo proteico.
ES2780692T3 (es) Constructo y secuencia para la expresión genética mejorada
JP2017501712A (ja) 単鎖ｉｌ−１２核酸、ポリペプチド、およびそれらの使用
MX2015012361A (es) Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
JP2019514417A5 (hr)
RU2020110331A (ru) Модификация т-клеток
JP2016517691A5 (hr)
HRP20201442T1 (hr) Poboljšano rekombinantno izražavanje proteina korištenjem hibridnog promotora chef1
WO2013060819A3 (en) Transient expression vectors, preparation and uses thereof
NZ601099A (en) Use of vip3ab in combination with cry1ca for management of resistant insects
TR201816314T4 (tr) Kimerik sitomegalovirüs promotörü ve güçlendirici dizileri içeren ekspresyon vektörleri.
HRP20210301T1 (hr) Djelotvorna selektivnost rekombinantnih proteina
DE602005026186D1 (de) 3-nichttranslatierte hybridbereiche mit eignung zur effizienten proteinexpression in säugerzellen
Al-Rubeai Antibody expression and production
JP2015516156A5 (hr)
ES2564227T3 (es) Elemento de ADN que tiene actividad de aumento de expresión de un gen exógeno
JP2014527801A5 (hr)
JP2010183921A5 (hr)